Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
← catalyst calendarSponsored by Revolution Medicines, Inc. (industry) · RVMD — their whole pipeline →.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
500actual
Sites
60
Countries
France, Germany, Italy +4
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-10-16 | actual | When the study began enrolling |
| Primary completion | Jun 2026 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Dec 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2024-10-03 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-02 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Pancreatic Cancer
- PDAC
- PDAC - Pancreatic Ductal Adenocarcinoma
Interventions
- Drug: RMC-6236
- Drug: Gemcitabine
- Drug: nab-paclitaxel
- Drug: Irinotecan
- Drug: Liposomal irinotecan
- Drug: 5-fluorouracil
- Drug: leucovorin
- Drug: Oxaliplatin
Primary outcomes
what the primary-completion date above is the date OFProgression free survival (PFS) in the RAS G12-mutant population
measured Up to approximately 3 years
Overall survival (OS) in the RAS G12-mutant population
measured Up to approximately 3 years
Publications
- PMID 42223072 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · RVMD's whole pipeline · Catalyst calendar · Every registered study · What changed